NAV

Bumadizone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bumadizone
DrugBank Accession Number
DB13286
Background

Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis and gout 1. Its use is restricted to these conditions, due to risks this drug poses 1.

Type
Small Molecule
Groups
Approved
Structure
3D
Similar Structures
Weight
Average: 326.396
Monoisotopic: 326.163042576
Chemical Formula
C19H22N2O3
Synonyms
  • bumadizona
  • Bumadizone
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbacavirBumadizone may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Abciximab.
AcebutololBumadizone may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Bumadizone.
AcemetacinThe risk or severity of adverse effects can be increased when Bumadizone is combined with Acemetacin.
Food Interactions
Not Available

Categories

ATC Codes
M01AB07 — Bumadizone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Anilides
Alternative Parents
Phenylhydrazines / Medium-chain fatty acids / Branched fatty acids / Amino fatty acids / 1,3-dicarbonyl compounds / Carboxylic acid hydrazides / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organonitrogen compounds
show 2 more
Substituents
1,3-dicarbonyl compound / Amino fatty acid / Anilide / Aromatic homomonocyclic compound / Branched fatty acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid hydrazide / Fatty acid
show 11 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carbohydrazide, monocarboxylic acid (CHEBI:76119)
Affected organisms
Not Available

Chemical Identifiers

UNII
ATD81G944M
CAS number
3583-64-0
InChI Key
FLWFHHFTIRLFPV-UHFFFAOYSA-N
InChI
InChI=1S/C19H22N2O3/c1-2-3-14-17(19(23)24)18(22)21(16-12-8-5-9-13-16)20-15-10-6-4-7-11-15/h4-13,17,20H,2-3,14H2,1H3,(H,23,24)
IUPAC Name
2-(N,N'-diphenylhydrazinecarbonyl)hexanoic acid
SMILES
CCCCC(C(O)=O)C(=O)N(NC1=CC=CC=C1)C1=CC=CC=C1

References

General References
  1. WHO - Consolidated list of products whoes consumption has been banned or withdrawn [Link]
ChemSpider
18080
RxNav
19847
ChEBI
76119
ChEMBL
CHEMBL2105456
Wikipedia
Bumadizone

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0541 mg/mLALOGPS
logP2.95ALOGPS
logP4.72Chemaxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.35Chemaxon
pKa (Strongest Basic)-7Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area69.64 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity93.54 m3·mol-1Chemaxon
Polarizability35.07 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-001l-5921000000-64ba0f4d10457d801152
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-01t9-0589000000-3f83acb2f4759d89824c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-003r-0594000000-bdb281d3e557c1b7626f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-007a-4900000000-6669be16e291b9382994
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-3900000000-f89b7f8ef0bbe6eecf00
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-05ox-9300000000-b82f69b2e637e2ec8b8a
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-066r-4900000000-44f4f1e365a7bfa8bd64
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-178.76625
predicted
DeepCCS 1.0 (2019)
[M+H]+181.12422
predicted
DeepCCS 1.0 (2019)
[M+Na]+188.72893
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:39 / Updated at February 21, 2021 18:54